ESC Congress 2026 Abstract
Recaticimab lowered cholesterol with or without coronary disease
A pooled analysis of four randomized trials in 1,120 people with high blood fats found reductions versus placebo after 12 or 16 weeks.A pooled analysis of four randomized trials in 1,120 people with high blood fats found reductions versus placebo after 12 or 16 weeks.
Meta-analysis · 1,120 peopleInterventions
Who was studied1,120 patients with hypercholesterolemia or mixed hyperlipidemia, against placebo
What changedRecaticimab lowered cholesterol versus placebo in patients with and without coronary artery disease
The catchDifferent statin use complicates comparing recaticimab’s effects between patients with and without coronary disease